
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific's strong growth potential is underscored by the positive developments observed in its Electrophysiology and Watchman divisions, which are expected to enhance top-line performance and operating leverage. The company's ability to achieve faster-than-expected sales growth, alongside ongoing margin expansion due to increased gross margins and operational efficiencies, indicates a favorable outlook for earnings per share growth. Additionally, Boston Scientific's diversified product portfolio and consistent track record of exceeding organic growth expectations since 2021 further support a robust future in the MedTech sector.
Bears say
Boston Scientific's stock outlook appears negative due to projected gross margin declines of approximately 40 basis points year-over-year for 2024, primarily driven by limitations related to the capital sale energy generator system component. The company faces significant risks, including potential market share losses in critical areas such as electrophysiology and structural heart sales, compounded by weaker-than-expected operating margin improvements and a bear case assumption of revenue growth remaining below 10%. Additionally, concerns about complacency following a strong revenue growth year, alongside potential disruptions from COVID-19 and competitive pressures, further contribute to an uncertain financial trajectory for the firm.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares